Julian Adams is the Chief Executive Officer of Stand Up To Cancer (SU2C), where he directs strategy, fundraising, and collaborative initiatives to accelerate cancer research and patient impact. He co-founded SU2C and has been instrumental in building its cross-industry and academic partnerships, raising hundreds of millions of dollars to fund collaborative research teams and innovative clinical trials.
Adams has led the launch of multiple SU2C “Dream Teams,” bringing together top researchers to focus on high-priority cancer areas, including pancreatic, lung, and pediatric cancers. He oversees programs that integrate translational research, clinical trials, and patient advocacy, ensuring that discoveries move rapidly from lab to clinic. Adams has also established SU2C’s collaborations with pharmaceutical and biotechnology companies to facilitate experimental therapeutics and precision oncology approaches, expanding access to cutting-edge treatments for patients nationwide.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential CEOs in Oncology in 2025 and stay tuned for other special category nominations
